← Back to Blog

VenaBlock® vs. Sclerotherapy: When Adhesive Closure Wins

January 15, 2026

Two Very Different Approaches

Sclerotherapy involves injecting a chemical agent (liquid or foam) directly into a vein, causing endothelial damage, thrombosis, and eventual fibrosis. VenaBlock® delivers cyanoacrylate adhesive that mechanically seals the vein wall without causing endothelial chemical destruction.

Both are minimally invasive, office-based procedures — but they have very different indications, efficacy profiles, and limitations.

Where Sclerotherapy Excels

Sclerotherapy remains the preferred treatment for:

  • Small-diameter superficial varicosities (<3 mm)
  • Spider veins and telangiectasias (liquid sclerotherapy)
  • Residual tributary veins following truncal ablation
  • Perforator vein incompetence (ultrasound-guided foam)

The Limitation of Sclerotherapy for Truncal Reflux

When applied to large-diameter truncal veins (GSV, SSV), sclerotherapy — even in foam form — produces significantly lower and less durable closure rates compared to endovenous thermal ablation or VenaBlock®. The dynamic blood flow in large saphenous veins rapidly dilutes the sclerosant before adequate wall contact is achieved.

Published 5-year data shows foam sclerotherapy GSV closure rates of 40–60% — far below the 91.1% at 5 years reported for VenaBlock®.

Side Effect Profiles

Sclerotherapy carries specific risks that VenaBlock® does not:

  • Visual disturbances and migraine: Associated with foam sclerotherapy, likely due to microbubble embolization through patent foramen ovale
  • Matting: Formation of new fine vessel networks around injected sites
  • Hyperpigmentation: Brown skin staining along treated veins, more common with larger vein sclerotherapy
  • Cutaneous necrosis: If sclerosant extravasates into surrounding tissue

The Complementary Relationship

In clinical practice, VenaBlock® and sclerotherapy are often used together: VenaBlock® ablates the incompetent saphenous trunk, eliminating the source of reflux, followed by ultrasound-guided foam sclerotherapy to treat residual tributary varicosities. This combination approach maximizes efficacy while minimizing invasiveness.